% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

  • sysintelfin sysintelfin Sep 18, 2012 8:34 AM Flag

    What kind of news heading is this?

    Healthcare Business Review: Threshold Fails Phase 2b, Gilead Shares Perform

    Unbelievable.......what a twist...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yesterday was all about the shorts having an opportunity to cover their #$%$

    • ANother Adam Fartstain type of reporter who does not either understand the study, or is just trying to cover for his hedge fund friends.

      Sentiment: Strong Buy

    • It is called inaccurate news. Here is what Threshold reported:

      "09/17/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that data from a randomized open-label Phase 2b clinical trial of investigational hypoxia-targeted drug TH-302 in patients with advanced pancreatic cancer will be presented at the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria, taking place September 28 - October 2, 2012.

      The company announced in February 2012 that the study met its primary endpoint demonstrating a statistically significant 63% improvement (p=0.005) in progression free survival (PFS) for patients treated with TH-302 and gemcitabine versus gemcitabine alone. This represented a 2-month increase in PFS for patients treated with TH-302.

      New findings on overall survival, which was a secondary endpoint of the study, indicate that patients treated with gemcitabine alone had a median overall survival of 6.9 months compared with 9.2 months for patients treated with 340 mg/m2 TH-302 plus gemcitabine (HR: 0.955, 95% CI: 0.67-1.37, p=0.800) and 8.7 months for patients treated with 240 mg/m2 TH-302 plus gemcitabine (HR: 0.960, 95% CI: 0.67-1.38, p=0.827). While not statistically significant, the improvement in median overall survival is consistent with the improvement in median PFS reported previously. The trial was not designed to detect a statistically significant improvement in overall survival and included a cross-over component. Patients receiving gemcitabine alone who crossed over to receive gemcitabine plus TH-302 upon disease progression did contribute to an increase in survival of the control arm."

      Real simple as to drugs, first one has to learn out to learn to use a drug to treat a patient. Cure comes later. Treatment can be beneficial even if a person does not get cured. Some cancers are curable. Some not. There is no question TH-302 is a beneficial treatment.

      Sentiment: Strong Buy

    • seems as though the word "failed" is being used pretty loosely, early ad often

      • 1 Reply to jamedash83
      • It did not fail. It had progress. That is the reason it is going into Phase 3. If it failed it would not be going to Phase 3.

        "We are pleased with the overall consistency of results from this study demonstrating activity of TH-302 and, as a consequence, a randomized Phase 3 trial of TH-302 in patients with advanced first-line pancreatic cancer is planned to be initiated together with our partner Merck KGaA," said Barry Selick, Ph.D., Chief Executive Officer of Threshold."

        Sentiment: Strong Buy

1.17-0.05(-4.10%)Sep 23 4:00 PMEDT